Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals, Inc. in a transaction valued at approximately $5.6 billion. The deal, structured as a tender offer, provides Apellis shareholders with $41.00 in cash per share, along with a non-transferable contingent value right (CVR) linked to future sales performance of the eye drug Syfovre.
Deal Structure and Premium
The acquisition price represents a significant premium of roughly 140% over Apellis's closing stock price on March 30, 2026. Following the announcement, Apellis shares traded near the offer price at $40.23. The CVR component could provide an additional $4.00 per share if Syfovre and related therapies achieve specific net sales milestones: $2.00 if annual sales reach $1.5 billion between 2027 and 2030, and another $2.00 if sales hit $2.0 billion in any year from 2027 through 2031.
Strategic Rationale for Biogen
For Biogen, the acquisition is a strategic move to bolster its portfolio beyond its core multiple sclerosis business, which has faced growth challenges. The deal immediately transfers two marketed products—Syfovre for geographic atrophy and Empaveli for certain blood disorders—along with Apellis's nephrology commercial team to Biogen. Biogen's CEO, Christopher Viehbacher, highlighted the transaction as an immediate step forward in the company's transformation, specifically noting the "intrinsic value" of Apellis's kidney disease assets. Analysts, such as Evan Seigerman from BMO Capital, suggest the deal could meaningfully alter Wall Street's perception of Biogen's near-term growth trajectory.
Financial Details and Approval
The Apellis board of directors has unanimously recommended the tender offer to shareholders. Key shareholders, including directors, executives, and Morningside Venture Investments—collectively owning about 14% of outstanding shares—have committed to tender their stock. The offer must remain open for 20 business days and requires a majority of shares to be tendered. Biogen plans to finance the acquisition through existing cash and new borrowings, expecting it to be accretive to adjusted earnings beginning in 2027. The companies anticipate closing the transaction in the second quarter of 2026, pending customary conditions including antitrust clearance and the tender of a majority of shares.
Product Portfolio and Market Context
Syfovre (pegcetacoplan) is Apellis's flagship therapy for geographic atrophy, a severe form of age-related macular degeneration. Despite competition from Astellas Pharma's Izervay, Apellis reported Syfovre maintained approximately 60% market share as of February 2026. However, its U.S. sales declined to $586.9 million in 2025 from $611.8 million the prior year. The drug carries safety warnings for rare but serious inflammatory eye conditions, including retinal vasculitis. Combined with Empaveli, which generated U.S. sales of $102.4 million in 2025, the two products brought Apellis total revenue of $689 million last year, with the company projecting mid- to high-teens percentage growth through at least 2028.
Contingencies and Risks
The transaction includes several contingencies. The CVRs could expire worthless if Syfovre fails to hit the stipulated sales targets. Furthermore, the agreement contains a break clause should the deal not close by September 30, 2026. Apellis CEO Cedric Francois stated the acquisition would "accelerate our impact," while Biogen views Apellis's kidney portfolio as a strategic platform for its own late-stage kidney drug candidate, felzartamab.
Biogen shares traded at $183.33 following the announcement, having slipped slightly as the market assessed the deal's price and the contingent milestones. The acquisition marks a major consolidation in the biotechnology sector, as large firms seek innovative assets to drive future growth.
